Melatonin supplements marketed to children contain -83% to +478% of labeled dosage, and pediatric ER visits for melatonin ingestion reached 11,000 between 2019-2022

Melatonin, sold as a dietary supplement and exempt from FDA pre-market approval under DSHEA (1994), has actual content ranging from 83% below to 478% above what is printed on the label, with the worst accuracy in chewable gummy formulations specifically marketed to children -- and nearly 1 in 5 school-age children now takes melatonin regularly for sleep. Why it matters: parents dosing children based on inaccurate labels may unknowingly administer hormone doses 2-5x higher than intended, so children's developing endocrine systems are exposed to supraphysiological melatonin levels with unknown long-term effects on puberty onset, circadian rhythm development, and reproductive hormones, so emergency room visits for pediatric melatonin ingestion reached approximately 11,000 between 2019 and 2022 according to the CDC, so the supplement industry's voluntary self-regulation response (CRN guidelines adopted March 2024 with an 18-month voluntary compliance window) is neither binding nor timely, so the regulatory vacuum persists while a generation of children serves as an uncontrolled experiment in chronic exogenous hormone supplementation. The structural root cause is that the 1994 Dietary Supplement Health and Education Act (DSHEA) classified melatonin as a dietary supplement rather than a drug or hormone, placing the burden of proof for safety on the FDA rather than the manufacturer, and no subsequent legislation has reclassified it despite melatonin being regulated as a prescription medication in the EU, UK, Australia, and Japan.